Royalty Pharma - Class A opened higher at $67.00, compared with its previous close of $65.93. In the last trading session, the stock traded between $66.40 and $67.53. It showed an upward intraday trend.
An investment of $100 made 5 years ago in Royalty Pharma - Class A is now worth
$ 170.16
giving a profit of
$ 70.16 (70.16%)
Note: Past profits do not guarantee future returns.
Rating from 7 Analysts
Today's Change
+$1.33 (+2.02%)
Day High
$67.53
Day Low
$66.40
Day Open
$67.00
Prev Close
$65.93
Volume
14,90,934
1W Return
5.53%
1M Return
15.53%
3M Return
13.73%
6M Return
35.91%
1Y Return
83.43%
Market Cap ($ Mn)
29,951
PE Ratio
32.37
PB Ratio
3.97
PEG Ratio
6.54
ROE
20.14%
ROCE
9.05%
EPS (TTM)
$0.04
1 Week
5.53%
1 Month
15.53%
3 Months
13.73%
6 Months
35.91%
9 Months
64.62%
Royalty Pharma stock returns 40.75% annually over last decade
Royalty Pharma delivered a 40.75% average annual return over the past decade. The stock outperformed the broader market by 27.34% on an annualized basis. A $1,000 investment made 10 years ago is now worth $30,201.97. The company currently has a market capitalization of $27.30 billion.
2mo agoRoyalty Pharma, Zealand Pharma close $100M rusfertide royalty deal
Royalty Pharma closes $100M deal for rusfertide rights, paying $50M upfront and $50M deferred. Zealand retains 0.25% royalty above $1.5B sales; Royalty gets 0.75%. FDA PDUFA date set for Q3 2026.
2mo agoRoyalty Pharma appoints Greg Raskin as head of academic initiatives
Royalty Pharma plc has appointed Greg Raskin as Senior Vice President, Head of Academic Initiatives, effective August 2026. Raskin will lead outreach with academic institutions and oversee the Royalty Pharma Translational Prize. He joins from Memorial Sloan Kettering Cancer Center, bringing extensive experience in technology development and healthcare investing.
2mo agoRoyalty Pharma buys cliramitug royalty interest for up to $425 million
Royalty Pharma acquired a royalty interest in AstraZeneca's cliramitug from Neurimmune for up to $425 million, including $125 million upfront, with an additional $125 million due in Q1 2027 and $175 million contingent on milestones. The deal grants a 3% to 4% royalty on worldwide net sales of cliramitug, a Phase 3 therapy for ATTR-CM with peak sales projected between $3 billion and $5 billion. The ATTR-CM market grew over 40% in 2025 to exceed $7 billion, driven by increasing diagnosis rates and new therapeutic options.
3mo agoRoyalty Pharma declares $0.235 per share dividend for Q3 2026
Royalty Pharma plc declared a dividend of $0.235 per Class A ordinary share for Q3 2026, payable on September 10, 2026, to shareholders of record on August 14, 2026.
3mo agoRoyalty Pharma to announce Q2 2026 financial results on August 5
Royalty Pharma plc is set to release its Q2 2026 financial results on August 5, 2026, prior to market open. A conference call and webcast are scheduled for 8:00 a.m. ET to review the quarterly performance. The company, established in 1996, holds royalties on over 35 commercial products and funds biopharmaceutical innovation.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $540.00 | +1.95% | $1,36,868.94M | 31.55 | |
| $61.07 | +2.12% | $1,31,639.87M | 14.39 | |
| $222.76 | +4.01% | $88,933.81M | - | |
| $818.77 | +0.68% | $82,808.76M | 19.64 | |
| $897.85 | +0.68% | $56,462.20M | 38.99 | |
| $371.56 | -0.48% | $40,792.43M | 65.60 | |
| $190.27 | +0.82% | $40,781.71M | - | |
| $56.49 | -1.40% | $35,253.15M | 26.24 | |
| $37.52 | +1.10% | $27,101.56M | - | |
| $111.59 | +15.07% | $24,369.25M | - | |
| $116.80 | -0.06% | $23,675.13M | 15.85 | |
| $174.00 | -25.13% | $23,282.77M | 39.98 |
An investment of $100 made 5 years ago in Royalty Pharma - Class A is now worth
$ 170.16
giving a profit of
$ 70.16 (70.16%)
Note: Past profits do not guarantee future returns.
